Figma Shares Indicated To Open $105/$110
LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE: ADCT), a pioneer in antibody drug conjugates (ADCs) with a current market capitalization of $131 million, has reported promising results from the LOTIS-7 Phase 1b clinical trial. The trial evaluated the combination of ZYNLONTA and glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). An overall response rate (ORR) of 95.5% and a complete response (CR) rate of 90.9% were observed among 22 evaluable patients. According to InvestingPro data, the company generated revenue of $70.8 million in the last twelve months while investing heavily in research and development.
The data, as of January 17, 2025, indicated that the median duration of response (DOR) was not reached. The safety profile was described as manageable, with neutropenia being the most common Grade ≥3 treatment-emergent adverse event. Other Grade 3/4 adverse events included generalized edema, pericardial effusion, and pneumonia, each reported in 3.2% of patients. For deeper insights into ADCT’s clinical pipeline and financial health, InvestingPro subscribers can access comprehensive research reports and additional ProTips.
The results will be presented at the European Hematology Association 2025 Congress (EHA2025) on Saturday, June 14, and at an oral encore presentation at the International Conference on Malignant Lymphoma (ICML) on Friday, June 20.
The LOTIS-7 study includes a multi-arm design to evaluate ZYNLONTA in combination with different agents for B-cell non-Hodgkin lymphoma (B-NHL). The primary endpoints of the study are safety and tolerability, with secondary efficacy endpoints including ORR, DOR, CRR, PFS, RFS, and OS.
ZYNLONTA, a CD19-directed ADC, has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Its mechanism involves binding to CD19-expressing cells, internalization, and the release of a potent payload leading to tumor cell death.
ADC Therapeutics is advancing its proprietary ADC technology with multiple ADCs in ongoing development for hematologic malignancies and solid tumors. The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey. While the company maintains a strong liquidity position with a current ratio of 3.82, InvestingPro analysis indicates the stock has experienced significant volatility, with a -67% return over the past year. The company’s Fair Value analysis and eight additional ProTips are available to InvestingPro subscribers.
This article is based on a press release statement from ADC Therapeutics.
In other recent news, ADC Therapeutics reported its fourth-quarter 2024 earnings, revealing a mixed financial performance. The company surpassed earnings per share expectations with a reported EPS of -$0.25, better than the anticipated -$0.43. However, revenue fell short at $16.91 million compared to the expected $18.85 million. Guggenheim Securities responded by lowering the price target for ADC Therapeutics to $7 from $10, while maintaining a Buy rating, indicating confidence in the company’s future despite recent revenue challenges. RBC Capital Markets maintained its Outperform rating with a steady price target of $8, emphasizing the significance of upcoming data updates for Zynlonta. The competitive landscape in the diffuse large B-cell lymphoma (DLBCL) market was noted as a factor impacting sales, with competition from CD20 bispecifics affecting Zynlonta’s performance. ADC Therapeutics plans to release key data updates in 2025, including results from the LOTIS-5 and LOTIS-7 trials, which are anticipated to be significant for the company’s growth strategy. The company ended 2024 with $251 million in cash and cash equivalents, providing a financial runway into the second half of 2026, as it focuses on expanding Zynlonta’s market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.